

Pathophysiological Interplay and Clinical Implications of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

Donaldo Emiliano Silva lopez¹, Thania Briones Díaz de León², Dayanna Alexandra Morán Ornelas², Orlando González Castro², María Fernanda Esqueda Soto³, Noemí Sarahi González Escareño³

¹Tecnológico de Monterrey Campus Monterrey, Nuevo León, Mexico

²Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, México

³Universidad Autonoma de Aguascalientes. Aguascalientes, México

ABSTRACT

Wolff-Parkinson-White (WPW) syndrome is a congenital cardiac conduction disorder characterized by the presence of an accessory pathway (AP) that facilitates abnormal ventricular preexcitation, predisposing affected individuals to potentially life-threatening arrhythmias. Among these, preexcited atrial fibrillation (AF) represents a critical clinical entity due to its propensity for rapid ventricular conduction, which may degenerate into ventricular fibrillation (VF) and sudden cardiac death (SCD). This review examines the intricate electrophysiological mechanisms underlying the coexistence of WPW and preexcited AF, emphasizing the role of anomalous atrioventricular (AV) conduction in perpetuating reentrant circuits and facilitating irregular, high-rate ventricular responses. Furthermore, we explore contemporary risk stratification paradigms, diagnostic modalities including 12-lead electrocardiography (ECG) and invasive electrophysiological studies (EPS), and evidence-based therapeutic approaches ranging from pharmacologic management to catheter ablation. By synthesizing current literature, this article aims to elucidate the clinical challenges and prognostic implications of preexcited AF in WPW syndrome, advocating for a tailored, patient-centric approach to mitigate adverse outcomes.

KEYWORDS: Wolff-Parkinson-White syndrome, preexcited atrial fibrillation, accessory pathway, ventricular preexcitation, sudden cardiac death, electrophysiological mechanisms, risk stratification, catheter ablation, antiarrhythmic therapy, reentrant tachycardia

ARTICLE DETAILS

Published On:
26 April 2025

Available on:
<https://ijmscrs.com/>

INTRODUCTION

Wolff-Parkinson-White syndrome is a well-documented cardiac electrophysiological anomaly resulting from the embryological persistence of an accessory atrioventricular pathway, typically composed of myocardial tissue that bypasses the normal AV nodal-His-Purkinje conduction system. This aberrant connection facilitates unopposed ventricular preexcitation, manifesting electrocardiographically as a shortened PR interval and a slurred QRS upstroke (delta wave). While many individuals with WPW remain asymptomatic, a subset experiences paroxysmal supraventricular tachycardias (PSVTs), most commonly orthodromic or antidromic atrioventricular reentrant tachycardias (AVRTs). However, the most ominous complication arises when atrial fibrillation—a chaotic,

disorganized atrial arrhythmia—conducts rapidly through the AP, leading to preexcited AF.^{1,2}

Preexcited AF poses a unique clinical challenge due to its unpredictable ventricular response rates, often exceeding 300 beats per minute, which can precipitate hemodynamic instability and degenerate into VF. The pathophysiological substrate for this phenomenon lies in the AP's ability to conduct atrial impulses without the inherent rate-limiting properties of the AV node, thereby facilitating a vicious cycle of electrical instability. Risk stratification in WPW patients hinges on identifying high-risk AP characteristics, such as short anterograde effective refractory periods (ERP <250 ms) or the presence of multiple pathways, which may predispose to malignant arrhythmias.²

Therapeutic strategies for preexcited AF encompass acute termination with AV nodal-blocking agents (contraindicated

Pathophysiological Interplay and Clinical Implications of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

in this context due to potential acceleration) or class I/III antiarrhythmics, alongside definitive treatment via catheter ablation to eliminate the AP. This review delves into the nuanced interplay between WPW and preexcited AF, offering insights into contemporary management protocols and underscoring the imperative for timely intervention to avert catastrophic outcomes.²

Pathophysiology of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

The pathophysiology of preexcited atrial fibrillation (AF) in Wolff-Parkinson-White (WPW) syndrome is a complex interplay of abnormal electrical conduction, myocardial excitability, and arrhythmogenic substrate formation, culminating in potentially life-threatening tachyarrhythmias. Central to this mechanism is the presence of an accessory pathway (AP), an embryological remnant of myocardial tissue that bridges the atria and ventricles outside the normal atrioventricular (AV) nodal-His-Purkinje axis. This anomalous connection permits unregulated anterograde or retrograde conduction, bypassing the intrinsic delay and decremental properties of the AV node, thereby establishing the electrophysiological conditions for both reentrant circuits and rapid ventricular activation during atrial fibrillation.³

In the context of WPW, the AP facilitates ventricular preexcitation by allowing atrial impulses to depolarize the ventricles prematurely, generating the characteristic electrocardiographic triad of a short PR interval (<120 ms), a slurred QRS upstroke (delta wave), and a widened QRS complex due to fusion between conduction through the AP and the normal AV nodal pathway. While this anatomical variant can remain electrically silent, it creates a substrate for macroreentrant tachycardias, most commonly orthodromic or antidromic AV reentrant tachycardia (AVRT). However, the most critical and potentially lethal scenario arises when atrial fibrillation—an irregular, disorganized atrial rhythm—is conducted rapidly through the AP, leading to preexcited AF.⁴ The transition from organized reentry to preexcited AF involves several pathophysiological mechanisms. First, the AP's ability to sustain extremely rapid conduction (often with effective refractory periods <250 ms) allows for unfiltered transmission of fibrillatory waves from the atria to the ventricles. Unlike the AV node, which exerts rate-limiting and decremental conduction properties, the AP lacks such protective mechanisms, permitting 1:1 conduction at rates that can exceed 300 beats per minute. This results in a highly irregular, broad-complex tachycardia with varying degrees of fusion, depending on the degree of simultaneous AV nodal conduction. The resulting hemodynamic instability is exacerbated by the loss of atrial kick, reduced ventricular filling time, and the potential for myocardial ischemia due to excessive oxygen demand.⁴

Moreover, the chaotic atrial activity in AF creates multiple wavelets that continuously bombard the AP, increasing the likelihood of extremely short RR intervals (<250 ms). When

these ultra-rapid impulses reach the ventricles during their vulnerable period (coinciding with the T wave), they may induce ventricular fibrillation (VF), a critical determinant of sudden cardiac death in WPW patients. The risk of such degeneration is further amplified by the presence of multiple APs, which create additional routes for reentry and increase the complexity of arrhythmia propagation.⁴

Structural and electrophysiological remodeling also contribute to the perpetuation of preexcited AF. Chronic preexcitation may lead to atrial dilatation and fibrosis due to chronic volume overload and abnormal activation patterns, fostering an arrhythmogenic atrial substrate. Additionally, the AP itself may exhibit anisotropic conduction, facilitating microreentry within the pathway and further destabilizing cardiac rhythm.⁵

In summary, the pathophysiology of preexcited AF in WPW syndrome is a multifactorial process involving abnormal bypass tracts, unfiltered rapid conduction, and an enhanced susceptibility to lethal ventricular arrhythmias. Understanding these mechanisms is essential for risk stratification, acute management, and definitive therapy, with catheter ablation of the AP remaining the gold standard for preventing recurrent arrhythmias and sudden cardiac death.⁵

Contemporary Diagnostic Modalities for Wolff-Parkinson-White Syndrome and Preexcited Atrial Fibrillation

The accurate diagnosis of Wolff-Parkinson-White (WPW) syndrome and its potentially lethal complication, preexcited atrial fibrillation (AF), requires a comprehensive, multimodal approach integrating non-invasive electrocardiographic assessment, advanced electrophysiological testing, and emerging imaging technologies. The primary objective of diagnostic evaluation is not only to confirm the presence of an accessory pathway (AP) but also to characterize its conduction properties, determine arrhythmic risk, and guide therapeutic decision-making to prevent sudden cardiac death.⁶

12-Lead Electrocardiography (ECG) and Ambulatory Monitoring

The initial diagnostic cornerstone remains the 12-lead electrocardiogram, which reveals the hallmark features of WPW syndrome: a shortened PR interval (<120 ms), a slurred QRS upstroke (delta wave), and secondary repolarization abnormalities manifesting as discordant ST-T wave changes. The polarity and morphology of the delta wave can provide preliminary localization of the AP, with positive deflections in lead V1 suggesting a left-sided pathway, while negative delta waves in inferior leads may indicate a posteroseptal or right-free-wall insertion.⁶

In cases of intermittent preexcitation, prolonged ambulatory monitoring (Holter or event recorders) may be employed to capture transient episodes of delta wave disappearance, which suggests a longer anterograde refractory period of the

Pathophysiological Interplay and Clinical Implications of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

AP and potentially lower risk for rapid conduction during AF. Exercise stress testing is another valuable tool, as the abrupt loss of preexcitation at higher heart rates implies poor AP conduction capacity, whereas persistent delta waves despite adrenergic stimulation may indicate a high-risk pathway.⁶

Transesophageal Electrophysiological Study (TEEPS) and Non-Invasive Programmed Stimulation

When surface ECG findings are equivocal or risk stratification is necessary, transesophageal atrial pacing can be utilized to assess AP properties non-invasively. By delivering incremental atrial extrastimuli, the effective refractory period (ERP) of the AP can be estimated; an ERP <250 ms is associated with increased susceptibility to rapid ventricular rates during AF. The induction of preexcited AF during such testing, though rare, is a definitive marker of high-risk physiology requiring urgent intervention.⁷

Invasive Electrophysiology Study (EPS) with Programmed Electrical Stimulation

The gold standard for definitive AP localization and risk assessment remains the invasive electrophysiology study, performed in a controlled catheterization laboratory setting. Multipolar electrode catheters positioned in the high right atrium, His bundle region, coronary sinus, and right ventricle allow for precise mapping of conduction intervals, retrograde versus anterograde pathway properties, and inducibility of reentrant tachycardias. Key parameters evaluated include:⁷

- **Anterograde AP ERP:** A short refractory period (<250 ms) correlates with rapid ventricular response during AF.⁷
- **Shortest preexcited RR interval during induced AF:** Intervals <250 ms predict a higher risk of ventricular fibrillation.⁷
- **Pathway location and multiplicity:** Multiple APs or septal pathways may necessitate more complex ablation strategies.⁷

Advanced Imaging and Three-Dimensional Electroanatomic Mapping

Emerging technologies such as three-dimensional electroanatomic mapping systems (CARTO, EnSite Precision) enhance the precision of AP localization by integrating real-time intracardiac electrograms with anatomical reconstruction. Fusion imaging with cardiac computed tomography (CT) or magnetic resonance imaging (MRI) can further delineate structural anomalies, particularly in cases of Ebstein's anomaly or other congenital defects associated with WPW.⁷

Differential Diagnosis and Provocative Testing

Preexcited AF must be distinguished from other wide-complex tachycardias, including polymorphic ventricular tachycardia (VT) and antidromic AVRT. Adenosine challenge testing can transiently block AV nodal conduction, unmasking pure AP-dependent activation, whereas

procainamide infusion may help differentiate between benign and high-risk pathways by assessing AP conduction suppression.⁸

In conclusion, the contemporary diagnostic algorithm for WPW and preexcited AF integrates electrocardiographic, electrophysiological, and imaging modalities to precisely characterize AP physiology, stratify arrhythmic risk, and guide definitive therapy. Early and accurate diagnosis is paramount to mitigating the threat of sudden cardiac death in this vulnerable patient population.⁸

Therapeutic Strategies for Wolff-Parkinson-White Syndrome and Preexcited Atrial Fibrillation: A Comprehensive Overview of Contemporary Interventions

The management of Wolff-Parkinson-White (WPW) syndrome complicated by preexcited atrial fibrillation (AF) requires a nuanced, multi-tiered therapeutic approach aimed at immediate arrhythmia termination, prevention of sudden cardiac death, and long-term cure of the underlying substrate. The treatment paradigm encompasses pharmacologic interventions for acute stabilization, electrical therapies for emergent situations, and definitive catheter ablation for permanent elimination of the accessory pathway (AP), with each modality tailored to the patient's hemodynamic status and arrhythmic risk profile.⁸

Acute Pharmacologic Management in the Emergency Setting

The immediate treatment of preexcited AF demands careful selection of antiarrhythmic agents that selectively target the AP while avoiding medications that may paradoxically accelerate ventricular response through AV nodal blockade. Class IC antiarrhythmics such as intravenous procainamide (10-15 mg/kg at 50 mg/min) or flecainide (2 mg/kg over 10-30 min) constitute first-line therapy due to their potent sodium channel blocking effects on the AP, which prolongs its refractory period and slows conduction velocity. These agents demonstrate particular efficacy in hemodynamically stable patients, with conversion rates to sinus rhythm exceeding 60-80% in clinical observations.⁸

Class III agents, specifically intravenous ibutilide (1 mg over 10 min, repeatable once) or amiodarone (150 mg bolus followed by infusion), serve as alternative options, particularly when atrial tissue stabilization is desired. However, their use requires cautious monitoring given ibutilide's proarrhythmic potential for torsades de pointes and amiodarone's complex multichannel effects that may initially paradoxically increase ventricular rates. Importantly, AV nodal blocking agents - including calcium channel blockers, beta-blockers, and digoxin - are absolutely contraindicated in the acute setting as they may precipitate ventricular fibrillation by eliminating the protective decremental conduction through the AV node while leaving the AP unopposed.⁸

Pathophysiological Interplay and Clinical Implications of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

Electrical Cardioversion as a Life-Saving Intervention

For patients presenting with hemodynamic instability, pre-syncope, or evidence of deteriorating cardiac output, immediate synchronized direct current cardioversion (100-200 J biphasic) represents the definitive emergency treatment. This approach guarantees instantaneous termination of the arrhythmia while circumventing the potential pitfalls of pharmacologic therapy. In refractory cases or when ventricular fibrillation ensues, escalation to higher energy levels (360 J) and prompt initiation of advanced cardiac life support protocols becomes imperative.⁹

Definitive Therapy: Catheter Ablation of the Accessory Pathway

Radiofrequency catheter ablation stands as the gold standard for definitive management of WPW syndrome, offering cure rates exceeding 95% in experienced centers. The procedure involves meticulous electrophysiological mapping to identify the AP's precise anatomical location using a combination of activation sequence analysis, pace mapping, and entrainment techniques. Contemporary approaches utilize three-dimensional electroanatomic mapping systems (CARTO, EnSite) integrated with fluoroscopic or intracardiac echocardiographic guidance to enhance spatial precision and reduce radiation exposure.⁹

Left-sided APs typically require transseptal or retrograde aortic access for ablation, while right-sided and septal pathways are approached via femoral venous access. The ablation target is the atrial or ventricular insertion site where the earliest preexcitation or retrograde conduction is recorded. Cryoablation has emerged as a valuable alternative for septal APs adjacent to the AV node, offering reversible lesion testing before permanent ablation to minimize the risk of heart block. Success is confirmed by the disappearance of delta waves and inability to induce AV reentrant tachycardia during post-procedural electrophysiological testing.¹⁰

Long-Term Pharmacologic Prophylaxis in Selected Cases

For patients who are not candidates for ablation or during the waiting period prior to the procedure, chronic antiarrhythmic prophylaxis may be considered. Class IC agents (flecainide, propafenone) or class III drugs (sotalol, dofetilide) can be employed with careful monitoring for proarrhythmic effects. However, this approach is generally regarded as a temporary measure given the superior efficacy and safety profile of catheter ablation.¹¹

Special Considerations in High-Risk Populations

Patients demonstrating high-risk features such as multiple APs, very short AP refractory periods (<220 ms), or history of cardiac arrest require particularly aggressive management. In these cases, same-hospitalization electrophysiology study and ablation is recommended, with consideration for temporary prophylactic antiarrhythmic therapy until the procedure can be performed. For pediatric populations or

patients with congenital heart disease, specialized ablation approaches accounting for anatomical variations are necessary, often requiring multidisciplinary team planning.¹²

Emerging Technologies and Future Directions

Novel therapeutic modalities under investigation include contact force-sensing ablation catheters for improved lesion formation, and magnetically guided robotic navigation systems for enhanced catheter stability. The advent of high-density mapping has further refined our ability to identify and target complex APs, while advances in pulsed field ablation may offer a potentially safer energy source for pathways located near critical conduction tissue.¹³

The comprehensive management of WPW syndrome with preexcited AF thus represents a continuum of care from emergency stabilization to definitive cure, with catheter ablation remaining the cornerstone of therapy. This approach not only eliminates the immediate threat of life-threatening arrhythmias but also provides long-term freedom from recurrent events and the psychological burden associated with this potentially lethal condition.¹⁴

CONCLUSIONS

The intricate interplay between Wolff-Parkinson-White (WPW) syndrome and preexcited atrial fibrillation (AF) represents one of the most clinically significant and potentially catastrophic electrophysiological phenomena in contemporary cardiology. This complex arrhythmogenic substrate, characterized by the coexistence of an accessory pathway (AP) with intrinsic rapid conduction properties and the chaotic electrical activity of atrial fibrillation, creates a perfect storm for hemodynamic compromise and sudden cardiac death. The comprehensive understanding of this condition demands recognition of its multifaceted nature, encompassing embryological, anatomical, electrophysiological, and clinical dimensions that collectively determine patient outcomes.

From a pathophysiological standpoint, the presence of an AP capable of unfiltered, rapid anterograde conduction fundamentally alters the cardiac electrical landscape, creating a vulnerable substrate where the normally protective decremental properties of the atrioventricular node are circumvented. The resulting unopposed transmission of fibrillatory waves to the ventricles at rates frequently exceeding 300 beats per minute not only compromises cardiac output through impaired ventricular filling and loss of atrial kick, but also creates the electrophysiological milieu for degeneration into ventricular fibrillation. This risk is further amplified in the presence of multiple APs or pathways with extremely short effective refractory periods (<250 ms), where the probability of impulse delivery during the ventricular vulnerable period increases exponentially.

The diagnostic evaluation of this condition has evolved significantly with technological advancements, transitioning from simple surface electrocardiographic analysis to

Pathophysiological Interplay and Clinical Implications of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

sophisticated multimodality assessment incorporating advanced signal processing, three-dimensional electroanatomic mapping, and provocative pharmacological testing. Contemporary risk stratification paradigms emphasize the critical importance of both non-invasive indicators (such as intermittent preexcitation and exercise-induced delta wave disappearance) and invasive electrophysiological parameters (particularly the shortest preexcited RR interval during induced AF). These diagnostic refinements have enabled more precise identification of high-risk patients who stand to benefit most from aggressive intervention, while sparing low-risk individuals from unnecessary procedures.

Therapeutic approaches have undergone remarkable transformation since the first recognition of this syndrome, with catheter ablation emerging as the undisputed gold standard for definitive management. The development of temperature-controlled radiofrequency ablation, cryoablation technologies, and advanced mapping systems has elevated success rates to >95% while minimizing complications, particularly for pathways in anatomically challenging locations near the AV node or in patients with complex congenital heart disease. The procedural evolution from blind anatomical approaches to precise activation sequence mapping represents one of the great success stories in interventional electrophysiology, fundamentally altering the natural history of this condition from one of potential sudden death to one of complete cure.¹²

Pharmacological management, while playing a secondary role in the modern era, retains importance in specific clinical scenarios, particularly for acute rhythm control in emergency settings and as a bridge to ablation in selected patients. The nuanced understanding of differential drug effects on the AV node versus accessory pathways has been crucial in avoiding therapeutic misadventures, particularly the now well-established contraindication of AV nodal blocking agents in acute presentations. The development of safer, more effective antiarrhythmic options continues to expand the pharmacologic armamentarium for temporary management of this condition.

Special populations, including pediatric patients, individuals with congenital heart disease, and those with multiple APs, present unique management challenges that demand tailored approaches. The recognition of WPW syndrome as not merely an electrical abnormality but often a marker of underlying structural heart disease (particularly Ebstein's anomaly) has important implications for comprehensive patient evaluation and management. Multidisciplinary collaboration between electrophysiologists, congenital heart specialists, and imaging experts has become increasingly important in optimizing outcomes for these complex cases. Looking forward, the field continues to evolve with promising technological innovations including contact force-sensing ablation catheters, high-density mapping systems,

and novel energy sources such as pulsed field ablation. These advances hold particular promise for addressing the remaining challenges in WPW management, including difficult anatomical locations, pediatric applications, and reducing already low complication rates further. Parallel developments in risk stratification, particularly through genetic profiling and advanced signal analysis of surface ECGs, may enable even more precise identification of at-risk individuals before catastrophic events occur.

In conclusion, WPW syndrome with preexcited AF stands as a paradigm of how profound understanding of basic electrophysiological principles, coupled with technological innovation and evidence-based clinical practice, can transform a once-feared condition into one that is not only manageable but curable. The journey from recognizing delta waves on a surface ECG to performing precise three-dimensional guided ablation exemplifies the remarkable progress in cardiac electrophysiology. Yet, the condition continues to remind clinicians of the vital importance of maintaining vigilance in ECG interpretation, prompt recognition of preexcited tachyarrhythmias, and timely referral for definitive therapy. As our understanding of the molecular biology of accessory pathways deepens and our therapeutic tools become ever more sophisticated, we move closer to the ultimate goal of eliminating entirely the risk of sudden death from this intriguing yet dangerous cardiac condition.

REFERENCES

- I. Moorman A, Webb S, Brown NA, Lamers W, Anderson RH. Development of the heart: (1) formation of the cardiac chambers and arterial trunks. *Heart*. 2003 Jul;89(7):806-14.
- II. Fitzsimmons PJ, McWhirter PD, Peterson DW, Kruyer WB. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators: a long-term follow-up of 22 years. *Am Heart J*. 2001 Sep;142(3):530-6
- III. Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard DJ, Holmes DR, Gersh BJ. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. *Circulation*. 1993 Mar;87(3):866-73.
- IV. Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A, Wellens HJ. Aborted sudden death in the Wolff-Parkinson-White syndrome. *Am J Cardiol*. 1995 Sep 01;76(7):492-4
- V. Wolff L, Parkinson J, White PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. 1930. *Ann Noninvasive Electrocardiol*. 2006 Oct;11(4):340-53.

Pathophysiological Interplay and Clinical Implications of Preexcited Atrial Fibrillation in Wolff-Parkinson-White Syndrome

- VI. Wilson FN. A case in which the vagus influenced the form of the ventricular complex of the electrocardiogram. 1915. *Ann Noninvasive Electrocardiol.* 2002 Apr;7(2):153-73.
- VII. Mirzoyev S, McLeod CJ, Asirvatham SJ. Embryology of the conduction system for the electrophysiologist. *Indian Pacing Electrophysiol J.* 2010 Aug 15;10(8):329-38.
- VIII. Colavita PG, Packer DL, Pressley JC, Ellenbogen KA, O'Callaghan WG, Gilbert MR, German LD. Frequency, diagnosis and clinical characteristics of patients with multiple accessory atrioventricular pathways. *Am J Cardiol.* 1987 Mar 01;59(6):601-6.
- IX. Zachariah JP, Walsh EP, Triedman JK, Berul CI, Cecchin F, Alexander ME, Bevilacqua LM. Multiple accessory pathways in the young: the impact of structural heart disease. *Am Heart J.* 2013 Jan;165(1):87-92.
- X. Kobza R, Toggweiler S, Dillier R, Abächerli R, Cuculi F, Frey F, Schmid JJ, Erne P. Prevalence of preexcitation in a young population of male Swiss conscripts. *Pacing Clin Electrophysiol.* 2011 Aug;34(8):949-53.
- XI. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of electrocardiographic preexcitation in men. The Manitoba Follow-up Study. *Ann Intern Med.* 1992 Mar 15;116(6):456-60.
- XII. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL, Roberts R. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. *N Engl J Med.* 2001 Jun 14;344(24):1823-31.
- XIII. LEV M, GIBSON S, MILLER RA. Ebstein's disease with Wolff-Parkinson-White syndrome; report of a case with a histopathologic study of possible conduction pathways. *Am Heart J.* 1955 May;49(5):724-41.
- XIV. Pediatric and Congenital Electrophysiology Society (PACES). Heart Rhythm Society (HRS). American College of Cardiology Foundation (ACCF). American Heart Association (AHA). American Academy of Pediatrics (AAP). Canadian Heart Rhythm Society (CHRS). Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S, Tanel RE. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). *Heart Rhythm.* 2012 Jun;9(6):1006-24.